Short Interest in Context Therapeutics Inc. (NASDAQ:CNTX) Expands By 55.1%

Context Therapeutics Inc. (NASDAQ:CNTX) was the target of a significant growth in short interest in the month of December. As of December 31st, there was short interest totalling 1,530,000 shares, a growth of 55.1% from the December 15th total of 986,300 shares. Approximately 2.6% of the shares of the company are short sold. Based on an average trading volume of 501,500 shares, the days-to-cover ratio is presently 3.1 days.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on CNTX. D. Boral Capital reaffirmed a “buy” rating and set a $9.00 target price on shares of Context Therapeutics in a research report on Wednesday. HC Wainwright restated a “buy” rating and set a $6.00 price objective on shares of Context Therapeutics in a report on Monday, September 23rd. Citizens Jmp upgraded shares of Context Therapeutics to a “strong-buy” rating in a research note on Wednesday, January 8th. Finally, JMP Securities began coverage on shares of Context Therapeutics in a research report on Wednesday, January 8th. They set an “outperform” rating and a $4.00 target price for the company. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $6.33.

Context Therapeutics Price Performance

NASDAQ:CNTX traded up $0.03 on Friday, reaching $1.01. 259,944 shares of the company’s stock were exchanged, compared to its average volume of 366,240. The firm has a market cap of $75.75 million, a price-to-earnings ratio of -1.11 and a beta of 2.10. The stock has a fifty day simple moving average of $1.36 and a 200-day simple moving average of $1.89. Context Therapeutics has a 52 week low of $0.89 and a 52 week high of $2.75.

Context Therapeutics (NASDAQ:CNTX) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.11). As a group, sell-side analysts predict that Context Therapeutics will post -0.51 EPS for the current year.

Hedge Funds Weigh In On Context Therapeutics

A number of large investors have recently made changes to their positions in the stock. Y Intercept Hong Kong Ltd purchased a new stake in Context Therapeutics during the 3rd quarter worth about $89,000. Clear Harbor Asset Management LLC lifted its holdings in shares of Context Therapeutics by 60.6% in the fourth quarter. Clear Harbor Asset Management LLC now owns 57,804 shares of the company’s stock worth $61,000 after buying an additional 21,804 shares in the last quarter. Renaissance Technologies LLC boosted its position in shares of Context Therapeutics by 63.4% in the second quarter. Renaissance Technologies LLC now owns 65,200 shares of the company’s stock valued at $131,000 after acquiring an additional 25,300 shares during the period. State Street Corp grew its stake in Context Therapeutics by 21.5% during the third quarter. State Street Corp now owns 111,907 shares of the company’s stock valued at $219,000 after acquiring an additional 19,800 shares in the last quarter. Finally, Affinity Asset Advisors LLC increased its holdings in Context Therapeutics by 392.4% during the 2nd quarter. Affinity Asset Advisors LLC now owns 1,619,140 shares of the company’s stock worth $3,246,000 after acquiring an additional 1,290,323 shares during the period. 14.03% of the stock is owned by institutional investors.

About Context Therapeutics

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.